Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SetPoint System in RRMS
NCT06796504Recruiting
- Sponsor
- SetPoint Medical
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Randomised, double-blind trial in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by SetPoint Medical. Primary endpoint: Incidence of adverse events at 96 weeks. Started Apr 2026; status: recruiting.
02
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT06796504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06796504.